In 2017, Monsanto (MON) peaked at $122.30 but ended the year at $118.80, delivering a return of 12.8% from stock appreciation alone.
The company is pending a merger with Bayer, but it is facing regulatory hurdles. Read The Bayer-Monsanto Merger Deal: An Update to learn more.
Eighteen Wall Street analysts are covering Monsanto. They have a consensus mean rating of 2.6 on the stock with an overall “hold” recommendation as of January 10, 2018. Monsanto’s ratings have remained unchanged from our last month’s update.
Of the 18 analysts, two have a “strong buy” recommendation for the company for the next 12-month period, while four have a “buy” recommendation for the stock.
Twelve analysts have a “hold” recommendation on Monsanto, and none of them have given it a “sell” or a “strong sell” recommendation.
As of January 10, 2018, the current consensus median price target for Monsanto is $128, which would leave an upside of 7.7% over its closing price of $118.80 that day.
The Royal Bank of Canada, BMO Capital Markets, Jefferies Group, and Piper Jaffray all have a price target of $128 for Monsanto stock. Wells Fargo upgraded its price target to $118 from $107.50 two months ago, and Barclays upgraded its price target to $124 from $120 at about the same time.
Next, let’s look at the ratings and price targets for FMC (FMC).